| First Author | Aghajanian H | Year | 2019 |
| Journal | Nature | Volume | 573 |
| Issue | 7774 | Pages | 430-433 |
| PubMed ID | 31511695 | Mgi Jnum | J:284616 |
| Mgi Id | MGI:6385968 | Doi | 10.1038/s41586-019-1546-z |
| Citation | Aghajanian H, et al. (2019) Targeting cardiac fibrosis with engineered T cells. Nature 573(7774):430-433 |
| abstractText | Fibrosis is observed in nearly every form of myocardial disease(1). Upon injury, cardiac fibroblasts in the heart begin to remodel the myocardium by depositing excess extracellular matrix, resulting in increased stiffness and reduced compliance of the tissue. Excessive cardiac fibrosis is an important factor in the progression of various forms of cardiac disease and heart failure(2). However, clinical interventions and therapies that target fibrosis remain limited(3). Here we demonstrate the efficacy of redirected T cell immunotherapy to specifically target pathological cardiac fibrosis in mice. We find that cardiac fibroblasts that express a xenogeneic antigen can be effectively targeted and ablated by adoptive transfer of antigen-specific CD8(+) T cells. Through expression analysis of the gene signatures of cardiac fibroblasts obtained from healthy and diseased human hearts, we identify an endogenous target of cardiac fibroblasts-fibroblast activation protein. Adoptive transfer of T cells that express a chimeric antigen receptor against fibroblast activation protein results in a significant reduction in cardiac fibrosis and restoration of function after injury in mice. These results provide proof-of-principle for the development of immunotherapeutic drugs for the treatment of cardiac disease. |
